Ocuphire Pharma rises as FDA accepts marketing application for eye drug

Opus Genetics

13/02/2023 14:20

** Shares of drug developer Ocuphire Pharma Inc  OCUP.O 
rise 6.7% to $3.50 premarket
    ** Company says U.S. Food and Drug Administration (FDA) has
accepted an application to approve its experimental eye drops to
reverse mydriasis
    ** Mydriasis refers to excessive or prolonged dilation of
pupils
    ** FDA will finalize its decision for the drug candidate,
Nyxol, by Sept. 28 - OCUP
    ** Nyxol is being developed to reverse mydriasis caused
during routine check-ups, disease monitoring or surgical
procedures, says company
    ** If approved, Nyxol will be the first prescription
reversal drop available for patients in the U.S. - OCUP
    ** Stock fell ~4% in the past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com))